Rhophylac®, manufactured by CSL Behring, will replace WinRHO-SDF as the Rh(D) immunoglobulin for intravenous use available within Australia. The change over from WinRho-SDF to Rhophylac® will occur when current stocks of WinRho-SDF are depleted which is anticipated to occur during August 2011.
Rhophylac® is indicated for use in large fetomaternal haemorrhage (FMH) where administration of intramuscular Rh(D) immunoglobulin is either contraindicated or not practical, or for inadvertent or emergency transfusion of Rh(D) positive blood to an Rh(D) negative female of childbearing potential.
The introduction of Rhophylac® will not affect the current Guidelines for the Prophylactic Use of Rh(D) Immunoglobulin (Anti-D) in Obstetrics.
Rhophylac can be accessed via the Australian Red Cross Blood Service.
Information for Haematologists and Transfusion Specialists 135 KB
Information for Obstetricians, Gynaecologists and Midwives 138 KB
Frequently asked questions 209 KB
